{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-21-005470","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.947309+00:00","generated_at":"2026-06-28T09:10:09.258639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement","bullets":["Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.","Ended Q3 with cash ~$19.7M and working capital ~$19.5M after July $12.5M private placement.","XCART platform progressing toward IND-enabling studies; issued US patent for co-administration with personalized vaccine.","PolyXen royalty income ~$0.3M from Takeda sublicense in Q3; partner Pharmsynthez filed Epolong registration in Russia."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-21-005470","json":"https://secwatch.observer/filing/0001683168-21-005470.json","markdown":"https://secwatch.observer/filing/0001683168-21-005470.md","text":"https://secwatch.observer/filing/0001683168-21-005470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316821005470/0001683168-21-005470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316821005470/xenetic_i8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:10:09.258639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}